18889881171
Kalkine 0
countryflagUS

Anika Therapeutics Inc

Healthcare US ANIK

11.05USD
-0.22(1.95%)

Last update at 2025-06-13T17:05:00Z

Day Range

11.0211.22
LowHigh

52 Week Range

16.0029.11
LowHigh

Fundamentals

  • Previous Close 11.27
  • Market Cap261.13M
  • Volume12096
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.05400M
  • Revenue TTM164.17M
  • Revenue Per Share TTM11.14
  • Gross Profit TTM 96.78M
  • Diluted EPS TTM-6.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -18.74600M 2.43M -28.62400M 36.12M 23.21M
Minority interest - - - - -
Net income -14.85900M 4.13M -23.98200M 27.19M 18.72M
Selling general administrative 84.79M 53.00M 60.06M 34.95M 34.34M
Selling and marketing expenses - - - - -
Gross profit 93.58M 82.94M 69.03M 85.86M 74.28M
Reconciled depreciation 14.49M 14.32M 13.46M 5.99M 5.91M
Ebit -33.88700M -18.48000M -14.46800M 28.26M 15.84M
Ebitda -19.40000M -39.57500M -0.61400M 34.25M 21.75M
Depreciation and amortization 14.49M -21.09500M 13.85M 5.99M 5.91M
Non operating income net other - - - - -
Operating income -19.40000M -18.48000M -14.46800M 34.25M 21.75M
Other operating expenses 175.64M 166.27M 144.93M 80.36M 83.81M
Interest expense 0.65M -0.18800M -0.30200M 7.86M 1.46M
Tax provision -3.88700M -1.70700M -4.64200M 8.93M 4.49M
Interest income - - - 1.87M 1.46M
Net interest income 0.65M -0.18800M -0.30200M 1.87M 1.46M
Extraordinary items - - - - -
Non recurring - - 42.52M - -
Other items - - - - -
Income tax expense -3.88700M -1.70700M -4.64200M 8.93M 4.49M
Total revenue 156.24M 147.79M 130.46M 114.61M 105.56M
Total operating expenses 112.98M 101.42M 83.49M 51.62M 52.53M
Cost of revenue 62.66M 64.85M 61.43M 28.75M 31.28M
Total other income expense net 0.65M 20.91M -14.15600M 1.87M 1.46M
Discontinued operations - - - - -
Net income from continuing ops -14.85900M 4.13M -23.98200M 27.19M 18.72M
Net income applicable to common shares -14.85900M 4.13M -23.98200M 27.19M 18.72M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 270.63M 349.13M 347.54M 365.61M 330.71M
Intangible assets 4.63M 74.60M 82.38M 91.16M 7.58M
Earning assets - - - - -
Other current assets 8.10M 8.83M 8.29M 8.75M 1.44M
Total liab 58.37M 63.56M 60.45M 93.20M 42.33M
Total stockholder equity 212.26M 285.56M 287.08M 272.40M 288.38M
Deferred long term liab - 6.44M 10.16M 11.89M 4.33M
Other current liab 17.83M 16.77M 4.32M 13.09M 11.30M
Common stock 0.15M 0.15M 0.14M 0.14M 0.14M
Capital stock 0.15M 0.15M 0.14M 0.14M 0.14M
Retained earnings 128.05M 210.72M 225.58M 221.44M 245.43M
Other liab - 6.83M 11.41M 35.46M 4.69M
Good will 7.57M 7.34M 7.78M 8.41M 7.69M
Other assets - 18.67M 20.29M 38.04M -1.44100M
Cash 72.87M 86.33M 94.39M 95.82M 157.46M
Cash and equivalents - - - - -
Total current liabilities 31.06M 27.91M 29.80M 36.87M 16.28M
Current deferred revenue 1.24M - 16.13M 13.21M -
Net debt -43.83000M -55.43700M -75.14600M -74.93800M -136.09600M
Short term debt 2.13M 2.07M 1.71M 1.58M 1.14M
Short long term debt - - - - -
Short long term debt total 29.04M 30.89M 19.24M 20.88M 21.37M
Other stockholder equity 90.01M 81.14M 67.08M 55.35M 48.71M
Property plant equipment - 48.28M 47.60M 50.61M 50.78M
Total current assets 163.31M 169.55M 168.53M 177.38M 235.75M
Long term investments - - - - -
Net tangible assets - 232.44M 216.16M 193.71M 294.47M
Short term investments - 34.63M - 2.50M 27.48M
Net receivables 35.96M 34.63M 29.84M 24.10M 23.08M
Long term debt - - - - -
Inventory 46.39M 39.77M 36.01M 46.21M 22.00M
Accounts payable 9.86M 9.07M 7.63M 8.98M 3.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -5.94300M -6.44300M -5.71800M -4.54200M -5.89800M
Additional paid in capital - - - - -
Common stock total equity - 0.15M 0.14M 0.14M 0.14M
Preferred stock total equity - - - - -
Retained earnings total equity - 210.72M 225.58M 221.44M 245.43M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.05M 17.22M 20.29M 15.42M 7.48M
Deferred long term asset charges - - - - -
Non current assets total 107.32M 179.58M 179.01M 188.22M 96.40M
Capital lease obligations 29.04M 28.82M 20.95M 20.88M 22.51M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -7.48600M 2.50M 24.96M 42.52M -45.60100M
Change to liabilities 2.96M 1.10M -1.39200M 3.49M 0.56M
Total cashflows from investing activities -7.48600M -3.11800M -71.26400M 39.69M -50.25700M
Net borrowings -0.28400M -0.20100M -0.35000M -0.55800M -0.55800M
Total cash from financing activities -4.85200M -6.77900M -3.77400M -8.14200M -28.90400M
Change to operating activities -2.72000M 0.53M -3.88600M 1.10M 2.21M
Net income -14.85900M 4.13M -23.98200M 27.19M 18.72M
Change in cash -8.05900M -1.43100M -61.64600M 68.42M -44.21400M
Begin period cash flow 94.39M 95.82M 157.46M 89.04M 133.26M
End period cash flow 86.33M 94.39M 95.82M 157.46M 89.04M
Total cash from operating activities 4.41M 8.40M 13.06M 37.01M 34.92M
Issuance of capital stock - - - - -
Depreciation 14.49M 14.32M 13.46M 5.99M 5.91M
Other cashflows from investing activities - -0.47600M -94.60100M 42.52M -45.60100M
Dividends paid - - - - -
Change to inventory -6.87300M -6.61900M -14.17700M -5.58500M -7.57700M
Change to account receivables -5.63000M -6.21600M 5.86M -1.83900M 2.91M
Sale purchase of stock 0.68M 1.13M 1.52M -30.00000M -30.00000M
Other cashflows from financing activities -4.56800M -6.57800M 46.78M 21.86M 1.10M
Change to netincome 14.75M -3.50900M 24.45M 9.29M 13.49M
Capital expenditures 7.49M 5.14M 1.63M 2.83M 4.66M
Change receivables -5.63000M -6.21600M 5.86M -1.83900M 2.91M
Cash flows other operating 7.36M 13.03M 8.87M -1.52700M 0.90M
Exchange rate changes - - - -0.13300M 0.03M
Cash and cash equivalents changes -7.92900M -1.50000M -61.97300M 68.42M -44.21400M
Change in working capital -11.82100M -14.71800M -13.45800M -6.64300M -3.20000M
Stock based compensation 14.31M 11.09M 5.39M 6.09M 11.05M
Other non cash items 7.56M -4.65500M 35.20M 3.58M 4.26M
Free cash flow -3.07700M 3.25M 11.44M 34.18M 30.26M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANIK
Anika Therapeutics Inc		 -0.22 1.95% 11.05 - 36.63 1.59 1.40 1.32 -72.6478
ZTS
Zoetis Inc		 -3.2725 1.94% 165.55 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.3 1.12% 26.54 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 4.73 3.60% 136.25 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.12 0.78% 15.27 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics Inc

32 Wiggins Avenue, Bedford, MA, United States, 01730

Key Executives

Name Title Year Born
Dr. Cheryl Renee Blanchard Ph.D. Pres, CEO & Director 1964
Mr. Michael L. Levitz Exec. VP, CFO & Treasurer 1974
Mr. David Colleran Exec. VP, Gen. Counsel & Corp. Sec. 1972
Ms. Anne Nunes VP of Operations NA
Mr. Mark Namaroff Exec. Director of Investor Relations & Corp. Communications 1963
Mr. Charles Sherwood III VP & Corp. Legal Counsel NA
Mr. James Chase Sr. VP of International Sales & Marketing NA
Mr. Bart Bracy VP of Sales & Marketing of Americas NA
Mr. Ben Joseph VP of Commercial & Corp. Devel. NA
Ms. Lisa Funiciello VP of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.